GlassScriptPhysician profile
Helen Shum
NPI 1821227273
$1,228.47
in general payments reported to CMS, 2019-2025
26 companies · $68.81 in 2025
The $68.81 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $310 · 2021: $317 · 2023: $33.20 · 2024: $129 · 2025: $68.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $173.41 | 2020-2021 | |
| Intuitive Surgical, INC. | $128.87 | 2024 | |
| Alexion Pharmaceuticals, INC. | $113.63 | 2019 | |
| Incyte Corporation | $98.79 | 2020 | |
| Global Blood Therapeutics, INC. | $91.69 | 2020-2021 | |
| Amgen INC. | $88.52 | 2020-2021 | |
| Gilead Sciences, INC. | $87.62 | 2019-2021 | |
| Tactile Systems Technology INC | $56.15 | 2021-2023 | Flexitouch Plus, Entre Plus |
| Pfizer INC. | $38.06 | 2019 | |
| Celgene Corporation | $33.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.43 | 2020 | |
| Genzyme Corporation | $29.08 | 2025 | |
| Kyowa Kirin, INC. | $28.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.95 | 2019 | |
| Menarini Silicon Biosystems, INC. | $23.53 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $20.37 | 2019 | |
| Merck Sharp & Dohme LLC | $19.90 | 2019 | |
| Servier Pharmaceuticals LLC | $19.29 | 2021 | |
| Astellas Pharma US INC | $18.33 | 2021 | |
| Eisai INC. | $17.71 | 2019 | |
| Csl Behring | $16.54 | 2019 | |
| Lilly USA, LLC | $16.27 | 2019 | |
| Dendreon Pharmaceuticals LLC | $16.20 | 2025 | Provenge |
| Seagen INC. | $15.00 | 2020 | |
| Janssen Biotech, INC. | $11.66 | 2021 | |
| Glaxosmithkline, LLC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Shum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.